Britain and America have signed a major trade agreement that will preserve zero tariffs on British drug products being sold in the US market.
Key Provisions of the Deal
As part of the deal, the UK has pledged to raise funding on drugs through the public health system. This pledge secures that import taxes on these crucial goods will be held at nothing for a timeframe of three years.
This deal follows previous threats to hike tariffs on patented drug products, with figures floated as high as 100%.
"This deal between the UK reinforces the global environment for innovative medicines and introduces long-overdue balance to American-British medicine commerce," an announcement said.
Commercial Importance
Pharmaceuticals constitute one of the UK's largest export categories to the US, which is by far the largest destination for leading British pharmaceutical firms.
Export figures reveal that in the one-year period to the end of last September, the UK sold drugs worth billions to the US. This amount made up a significant portion of total UK exports in that timeframe.
"This guarantee protects jobs, stimulates capital expenditure and paves the way for the UK to establish itself as a international leader for medical research," a government official stated.
Key British Pledges
The agreement includes several key changes from the United Kingdom:
- Revised Affordability Limit: The UK will increase the affordability limit at which it deems new treatments to be unaffordable by 25%.
- Boosted Medicine Funding: There is a aim to raise total NHS spending on medicines from 0.3% of GDP to 0.6% over the coming ten years.
- Refund Ceiling: The percentage manufacturers must return to the NHS to prevent overspending will be restricted at fifteen percent. In the past, rebates topped twenty percent.
Broader Context
This agreement takes place against a long-running dispute between the sector and the ministers over drug pricing and regulatory access.
This friction were heightened by arguments that American patients were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several significant pharmaceutical investments in the UK have been delayed or cancelled, while substantial expansions have been directed toward US facilities.
The Science Minister acknowledged that the NHS must spend more on drugs, noting that its budget allocation on drugs had decreased as a percentage of its resources over the previous ten-year period.
